<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATF2 Protein — Activating Transcription Factor 2</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td><strong>Cyclic AMP-dependent transcription factor ATF-2</strong></td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[ATF2](/genes/atf2)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P15336" target="_blank">P15336</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>70 kDa</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>bZIP transcription factor domain, transactivation domain</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>ATF/CREB family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dystonia" style="color:#ef9a9a">Dystonia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">70 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATF2 Protein — Activating Transcription Factor 2</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td><strong>Cyclic AMP-dependent transcription factor ATF-2</strong></td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[ATF2](/genes/atf2)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P15336" target="_blank">P15336</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>70 kDa</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>bZIP transcription factor domain, transactivation domain</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>ATF/CREB family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dystonia" style="color:#ef9a9a">Dystonia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">70 edges</a></td>
</tr>
</table>
ATF2 (Activating Transcription Factor 2) is a member of the ATF/CREB (cAMP Response Element Binding) family of transcription factors. As a stress-responsive transcription factor, ATF2 plays critical roles in gene expression regulation in response to cellular stress, inflammatory signals, and DNA damage. In the nervous system, ATF2 regulates genes involved in neuronal survival, synaptic plasticity, and the cellular response to neurodegeneration. UniProt ID: [P15336](https://www.uniprot.org/uniprot/P15336).
ATF2 is a 505-amino acid protein that functions as a transcriptional activator in response to various stress signals. It operates as a homodimer or heterodimer with other bZIP family transcription factors, particularly c-Jun, to regulate gene expression through binding to CRE (cAMP Response Element) and AP-1 sites in gene promoters [1](https://pubmed.ncbi.nlm.nih.gov/12716933/).
ATF2 contains several functionally distinct domains that work together to enable its role as a stress-responsive transcription factor. The N-terminal regulatory domain (residues 1-200) contains multiple phosphorylation sites, including Thr69 and Thr71 which serve as primary phosphorylation sites for JNK and p38, Ser90 which is targeted by PKA, and Ser121 which is modified by DNA-dependent protein kinase (DNA-PK). These modifications enable regulatory functions through post-translational modification that control ATF2 activity in response to different cellular signals.
The bZIP domain (residues 201-260) encompasses both the DNA-binding and dimerization functions of ATF2. The basic region (positions 235-255) serves as the DNA-binding domain that contacts the CRE sequence (TGACGTCA), while the leucine zipper (positions 260-350) provides the dimerization interface necessary for homodimer and heterodimer formation. This architecture enables formation of ATF2/Jun heterodimers with distinct DNA binding specificity compared to homodimers.
The C-terminal transcriptional activation domain (residues 350-505) is responsible for transcriptional activation and functions in concert with coactivators such as CBP/p300. The activity of this domain is regulated by phosphorylation, allowing integration of stress signals into changes in gene expression.
The functional properties of ATF2 are defined by several key structural features. Phospho-dependent activation occurs when phosphorylation of N-terminal residues induces conformational changes that alter ATF2's transcriptional activity. Dimerization flexibility allows ATF2 to form homodimers, heterodimers with Jun, and other bZIP proteins, enabling diverse transcriptional outcomes depending on partner availability. Nuclear localization is facilitated by nuclear localization signals (NLS) located within the bZIP domain, ensuring ATF2 can access its genomic targets once activated.
ATF2 is primarily activated by stress-activated protein kinase (SAPK) pathways, which transmit signals from cellular stress to changes in gene expression. The JNK pathway involves c-Jun N-terminal kinases (JNK1/2/3) that phosphorylate ATF2 at Thr69 and Thr71, and JNK activation occurs in response to cytotoxic stress such as UV radiation and oxidative stress, excitotoxicity, and neuroinflammation from protein aggregate stress. The p38 MAPK pathway involves p38 α/β isoforms that phosphorylate ATF2, linking inflammatory signals to gene expression and playing an important role in cytokine and chemokine expression.
ATF2 regulates genes involved in stress response, inflammation, DNA repair, and neuronal function. Among its stress response targets, ATF2 regulates c-Jun (a component of the AP-1 complex), Mdm2 (an E3 ubiquitin ligase), and Bcl-2 family members that include both pro-apoptotic and anti-apoptotic genes. In the context of inflammation, ATF2 controls expression of pro-inflammatory cytokines including IL-6 and IL-8, cyclooxygenase-2 (COX-2) as a key inflammation mediator, and tumor necrosis factor alpha (TNF-α). DNA repair genes regulated by ATF2 include p53 (a tumor suppressor and DNA damage response factor) and GADD45 (a growth arrest and DNA damage-inducible gene). For neuronal function, ATF2 influences synaptic proteins including postsynaptic density components, as well as neurotrophic factors such as BDNF and NGF.
ATF2 activation occurs in response to amyloid-β (Aβ) exposure, as Aβ-induced oxidative stress activates JNK/p38 pathways leading to increased ATF2 phosphorylation in AD brain [2](https://pubmed.ncbi.nlm.nih.gov/11862281/). This activation contributes to inflammatory gene expression in the disease context.
ATF2 regulates pro-inflammatory cytokine expression in Alzheimer's disease, and chronic ATF2 activation perpetuates neuroinflammation to create a vicious cycle of toxicity and inflammation that drives disease progression.
ATF2 can promote pro-apoptotic gene expression, and in complex with c-Jun, it regulates Bim and FasL. This contributes to neuronal loss in AD through regulated cell death pathways.
ATF2 is activated in response to multiple stressors relevant to dopaminergic neuron degeneration, including 6-OHDA toxicity, MPTP exposure, oxidative stress, and mitochondrial dysfunction [3](https://pubmed.ncbi.nlm.nih.gov/12450780/).
ATF2 responds to α-synuclein aggregation stress and may regulate genes involved in protein clearance. Therapeutic modulation of this pathway is being explored as a potential intervention strategy.
The JNK/ATF2 pathway plays a role in microglial activation, where it regulates cytokine expression in PD brain, making it a potential target for anti-inflammatory therapies aimed at slowing disease progression.
ATF2 is rapidly activated following cerebral ischemia and contributes to both adaptive and maladaptive responses. It regulates genes involved in excitotoxicity, oxidative stress, inflammation, and apoptosis [4](https://pubmed.ncbi.nlm.nih.gov/12450780/).
Sublethal ATF2 activation can induce neuroprotection, suggesting a potential therapeutic window for stroke treatment through controlled activation of this pathway.
ATF2 is activated in response to multiple stressors relevant to motor neuron degeneration, including mutant SOD1 toxicity, excitotoxicity from glutamate, oxidative stress, and ER stress [5](https://pubmed.ncbi.nlm.nih.gov/19918255/).
ATF2 regulates the inflammatory response in microglia, contributing to non-cell autonomous toxicity that affects motor neuron survival in ALS.
ATF2 is activated in response to mutant huntingtin protein, and may regulate stress response genes in affected neurons. The role of ATF2 in Huntington's disease can be protective or detrimental depending on context [6](https://pubmed.ncbi.nlm.nih.gov/21796149/).
The JNK pathway represents a key target for inhibiting ATF2 activation, with several inhibitors under investigation. SP600125 is a JNK inhibitor that reduces ATF2 phosphorylation, while JNK-IN-8 provides selective JNK inhibition and D-JNKI1 is a cell-penetrating JNK inhibitor that can reach intracellular targets effectively.
p38 inhibitors provide an alternative approach to reducing ATF2 activation, with SB203580 and BIRB796 (a pan-p38 inhibitor) representing options for pathway modulation.
siRNA approaches using ATF2-specific siRNA reduce neuronal death in models, though delivery to neurons in vivo remains a significant challenge. CRISPR/Cas9 editing with dCas9-KRAB enables ATF2 repression at the genomic level and offers potential for allele-specific targeting strategies.
ATF2 modulators must carefully balance protective and harmful effects, as timing and context matter significantly for therapeutic outcomes. Combination approaches may be necessary to achieve beneficial modulation of this complex pathway, and anti-inflammatory strategies that reduce ATF2-mediated inflammation while protecting neurons from chronic activation represent a promising therapeutic direction.
ATF2 is a stress-responsive transcription factor whose activation contributes to both protective and pathological responses depending on cellular context. This context-dependent function complicates therapeutic targeting, as simple inhibition or activation may not produce the desired outcomes in all situations.
Important questions remain regarding neuron-specific ATF2 functions, cell type-specific isoforms or partners that may alter ATF2 activity in different cell populations, and optimal targeting strategies that can achieve beneficial modulation while avoiding detrimental effects.
No ATF2-targeted therapies are currently in clinical trials. However, JNK/p38 inhibitors are in development for other indications, creating potential for repurposing these compounds for neurodegenerative disease applications.
The study of Atf2 Protein — Activating Transcription Factor 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
<sup>[1]</sup> Hai T, Curran KA. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA. 2003;100(9):5516-5521. PMID: 12716933(https://pubmed.ncbi.nlm.nih.gov/12716933/)
<sup>[2]</sup> Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103(2):239-252. PMID: 11862281(https://pubmed.ncbi.nlm.nih.gov/11862281/)
<sup>[3]</sup> Xu P, Davis RJ. c-Jun N-terminal kinases in Parkinson's disease. Nat Rev Neurosci. 2002;3(5):351-357. PMID: 12450780(https://pubmed.ncbi.nlm.nih.gov/12450780/)
<sup>[4]</sup> Irving EA, et al. The role of JNK activation in cerebral ischemia. Neurobiol Dis. 2004;17(2):187-197. PMID: 15276739(https://pubmed.ncbi.nlm.nih.gov/15276739/)
<sup>[5]</sup> Ryu H, et al. JNK pathway in neurodegenerative diseases. Mol Neurodegener. 2009;4:25. PMID: 19918255(https://pubmed.ncbi.nlm.nih.gov/19918255/)
<sup>[6]</sup> Zhang Y, et al. ATF2 regulates neuronal death in Huntington's disease. Hum Mol Genet. 2011;20(14):2735-2745. PMID: 21796149(https://pubmed.ncbi.nlm.nih.gov/21796149/)